首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1532555

注射細胞毒性藥物市場 - 按藥物類別（抗代謝物、長春花生物鹼、紫杉烷類、蒽環類、鉑化合物、烷化劑）、按應用（腫瘤、類風濕關節炎）、按配銷通路- 預測（2024 - 2032）

Injectable Cytotoxic Drugs Market - By Drug Class (Antimetabolites, Vinca Alkaloids, Taxanes, Anthracyclines, Platinum Compounds, Alkylating Agents), By Application (Oncology, Rheumatoid Arthritis), By Distribution Channel - Forecast (2024 - 2032)

出版日期: 2024年05月23日 | 出版商:

Global Market Insights Inc. | 英文 119 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在藥物配方進步和腫瘤藥物開發成長的推動下，2024年至2032年全球注射細胞毒性藥物市場複合年成長率將達到5.8%。藥物配方的創新，例如即用型注射劑和改進的輸送系統，提高了治療效率和患者的依從性。此外，新的腫瘤藥物的持續開發擴大了可用療法的範圍，為各種癌症提供了更有針對性和更有效的治療選擇。這些進步透過滿足不斷變化的臨床需求和增加患者獲得先進治療的機會來改善治療結果並刺激市場成長。

例如，2023 年 6 月，美國 FDA 批准了 Amneal Pharmaceuticals 的 PEMRYDI RTU，這是一種即用型腫瘤注射。它適用於轉移性非鱗狀非小細胞肺癌的初始治療，與派姆單抗和鉑類化療一起用於無特定基因組突變的患者。這項批准凸顯了注射細胞毒性藥物的持續創新，特別是對於複雜的癌症治療。它強調了對個人化醫療和聯合療法的日益關注，這可能會推動對先進注射細胞毒性藥物的需求增加，並有助於市場成長和多元化。

注射細胞毒性藥物產業根據類別、應用、配銷通路和地區進行分類。

由於長春花生物鹼在治療白血病和淋巴瘤等多種癌症方面的功效已被證實，因此到 2032 年，長春花生物鹼領域將出現顯著的改善。這些藥物，如長春新鹼和長春花鹼，透過破壞癌細胞分裂發揮作用，這使得它們在化療方案中至關重要。它們有據可查的成功和在腫瘤學領域的持續使用有助於其佔據市場主導地位。新配方和聯合療法的持續開發進一步支持了長春花生物鹼領域的成長和突出。

由於這種慢性發炎性疾病的高盛行率以及細胞毒性藥物在治療嚴重病例方面的有效性，類風濕性關節炎細分市場將在 2024 年至 2032 年間出現顯著的激增。注射細胞毒性藥物，例如甲氨蝶呤，對於減少發炎和減緩疾病進展至關重要，可以顯著緩解患者的症狀。人們對治療方案的認知不斷提高，以及這些療法在類風濕性關節炎治療中的採用率不斷提高，推動了該細分市場的突出地位，從而奠定了其領先的市場地位。

由於醫療基礎設施的快速發展和癌症發生率的上升，亞太地區注射細胞毒性藥物市場將在 2024 年至 2032 年間獲得相當大的佔有率。該地區不斷成長的人口、癌症治療意識的提高以及對醫療保健技術的大量投資推動了對先進注射細胞毒性藥物的需求。此外，主要製藥公司的存在和強勁的研發活動進一步支持了市場成長。亞太地區充滿活力的醫療保健格局和對改善癌症護理的關注使其成為全球注射細胞毒性藥物行業的關鍵貢獻者。

產業生態系統分析
產業影響力
- 成長動力
  - 癌症和類風濕性關節炎的發生率增加
  - 越來越多的監管機構批准注射細胞毒性藥物
  - 增加對精準腫瘤療法開發的投資
  - 癌症護理設施迅速增加
- 產業陷阱與挑戰
  - 藥物研發成本高
  - 強力的替代療法的存在
成長潛力分析
未來市場趨勢
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
抗代謝藥
長春花生物鹼
紫杉烷類
蒽環類藥物
鉑化合物
烷基化劑
其他藥物類別

第 6 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
腫瘤學
類風濕關節炎
多發性硬化症
其他應用

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abbvie Inc
Accord Healthcare, Inc.
Amgen, Inc.
Baxter International Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Fresenius Kabi AG
Johnson and Johnson Services Inc.
Merck & Co. Inc.
Novartis AG
Pfizer, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9610

Global Injectable Cytotoxic Drugs Market will garner a 5.8% CAGR from 2024 to 2032, fueled by advancements in drug formulations and growth in oncology drug development. Innovations in drug formulations, such as ready-to-use injectables and improved delivery systems, enhance treatment efficiency and patient compliance. Furthermore, the continuous development of new oncology drugs expands the range of available therapies, offering more targeted and effective treatment options for various cancers. These advancements improve therapeutic outcomes and stimulate market growth by addressing evolving clinical needs and increasing patient access to advanced treatments.

For instance, in June 2023, the US FDA approved Amneal Pharmaceuticals' PEMRYDI RTU, a ready-to-use oncology injectable. It is indicated for initial treatment of metastatic non-squamous non-small cell lung cancer, used with pembrolizumab and platinum chemotherapy in patients without specific genomic mutations. The approval highlights the ongoing innovation in injectable cytotoxic drugs, particularly for complex cancer treatments. It underscores a growing focus on personalized medicine and combination therapies, which could drive increased demand for advanced injectable cytotoxic drugs and contribute to market growth and diversification.

The injectable cytotoxic drugs industry is classified based on class, application, distribution channel, and region.

The vinca alkaloids segment will encounter a marked upturn through 2032 due to their established efficacy in treating various cancers, including leukemia and lymphoma. These drugs, such as vincristine and vinblastine, work by disrupting cancer cell division, making them essential in chemotherapy regimens. Their well-documented success and continued use in oncology contribute to their dominant market position. The ongoing development of new formulations and combination therapies further supports the growth and prominence of the vinca alkaloids segment.

The rheumatoid arthritis segment will observe a noteworthy surge between 2024 and 2032, driven by the high prevalence of this chronic inflammatory condition and the effectiveness of cytotoxic drugs in managing severe cases. Injectable cytotoxic drugs, such as methotrexate, are crucial in reducing inflammation and slowing disease progression, providing significant relief for patients. The growing awareness of treatment options and increasing adoption of these therapies in rheumatoid arthritis management drive the segment's prominence, contributing to its leading market position.

Asia Pacific injectable cytotoxic drugs market will achieve a decent share from 2024 to 2032, attributed to rapidly growing healthcare infrastructure and increasing incidence of cancer. The region's expanding population, rising awareness of cancer treatments, and substantial investments in healthcare technology drive demand for advanced injectable cytotoxic drugs. Additionally, the presence of major pharmaceutical companies and robust R&D activities further support market growth. Asia Pacific's dynamic healthcare landscape and focus on improving cancer care position it as a pivotal contributor to the global injectable cytotoxic drugs industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cancer and rheumatoid arthritis
  - 3.2.1.2 Growing regulatory approvals for injectable cytotoxic drugs
  - 3.2.1.3 Increasing investments for the development of precision oncology therapies
  - 3.2.1.4 Rapid increase in cancer care facilities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High drug development cost
  - 3.2.2.2 Presence of strong alternative therapies
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Antimetabolites
5.3 Vinca alkaloids
5.4 Taxanes
5.5 Anthracyclines
5.6 Platinum compounds
5.7 Alkylating agents
5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oncology
7.3 Rheumatoid arthritis
7.4 Multiple sclerosis
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa